Development of promoterome analysis platform for combinatorial drug effects

点击翻译按钮获取中文摘要

We tried to evaluate whether drug effects and/or combinatorial drug effects can be represented by promoter activity profiles. We found that effect(promoter profile) of Gefitinib, an inhibitor of mutated-EGFR in MCF7 cells, can be represented by those of U0126 and Wortmannin, the potent inhibitors of the downstream signal transductions. However, it was hard to precisely predict combinatorial drug effects(profiles) by using the single drug profiles. We concluded that we have established the promoter-based platform to analyze drug effects.